High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
about
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domainsThe tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virusScavenger receptor BI and BII expression levels modulate hepatitis C virus infectivityInitiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type IGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationThe hepatitis C virus glycan shield and evasion of the humoral immune responseA focus reduction neutralization assay for hepatitis C virus neutralizing antibodiesThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope ProteinHigh-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density LipoproteinHuman combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virusTargeting host factors: A novel rationale for the management of hepatitis C virusHepatoma Cell Density Promotes Claudin-1 and Scavenger Receptor BI Expression and Hepatitis C Virus InternalizationApolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus ParticlesRole of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular DeterminantsIdentification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysisMutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agentsInterplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI.Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle.Hepatitis C virus entry.Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity.Role of lipid metabolism in hepatitis C virus assembly and entry.Adaptive immunity to the hepatitis C virus.Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation.Hepatitis C virus evasion mechanisms from neutralizing antibodiesTargeting HCV entry for development of therapeutics.Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus.Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.HCV entry and neutralizing antibodies: lessons from viral variants.Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.Association of lipid profile alterations with severe forms of dengue in humans.Antibodies to the high-density lipoprotein receptor SR-B1 potently inhibit hepatitis C virus replication in vivo: New avenues for preventing reinfection of the liver following transplantation.Hepatitis C virus: Morphogenesis, infection and therapy.
P2860
Q21089621-BE0D2AE4-1457-408B-94CB-8ED9DB58198DQ24652906-68123CD2-66BB-4496-AEC9-B72832D0F0DAQ24672232-24A347FD-F8F8-4F4D-A961-B3AF477C88CBQ24676039-3D58C3A4-FBCF-41DC-9B88-88A27C268F53Q26801759-3ED684B3-2C69-47A1-AA3E-9EFF3B3D4105Q26864485-0E0F364F-A22C-45FE-8535-720E260C0D91Q27023390-60A082D5-26BD-4CB1-BAD5-3EDCA966A181Q27478295-4BD4DDF3-BD7B-45D1-AF41-768789503DE0Q27481009-FF4B9730-5878-4570-8D68-D62A20AA4563Q27481010-3D90C44C-BC43-456F-8B62-27D3D8D9E727Q27481388-6276FF32-A1AE-4C46-8B38-1735C81E6573Q27488999-CDFC94E6-FEA0-4409-8841-74FD0AA95BA4Q27490466-4586603B-A2B7-4957-BF05-D5A762C0959FQ27490474-3AF69C66-88C5-4513-B933-2441B5367B10Q27490535-06CAA8AE-0BD9-4E33-BBE8-E0BCD07A32B2Q33712188-69F68702-78D9-4BBF-92B6-8B07F1496494Q33877381-B47EF50C-FC20-4F05-802F-7CAAA44C3067Q34295953-9CA4377A-792E-49E1-9A73-A517D9A30314Q34416004-3EF7BA1F-58C1-4366-A904-0507DBB0D1D8Q34540988-C66E2A93-EB21-4C86-95D3-F21BDA3B92E1Q34876325-ECDBBFC9-079D-4839-9FA3-ED52906199ABQ35076885-A4BD4C8D-055B-44B4-8A61-894C14476421Q35828072-3B8F9202-0572-4857-9E01-735C04937F74Q36933791-AA6EF928-D240-413F-AA63-3455DFEE7C8DQ36946317-0E651B6F-6AC3-4B9C-8C57-72B28661F655Q37330041-42539D18-6819-47EF-AC7C-417B91C2A46CQ37621569-3ABA61A3-59B7-480A-88E7-036A5C03CA56Q37805839-C69670CE-EC9F-45A2-B6B9-23E6362081A6Q37864742-05FFF375-7716-44C8-A227-99B48DC2551FQ37967737-D47F4061-D524-4116-8309-31BD06EF7C27Q38615654-7D96CDF0-56D2-479E-A163-DFA25F50CE1EQ38985716-CFEECD35-7054-4E20-A2E5-8CF10E021463Q39318833-0D4AAFD8-74C2-4E1F-816F-A461893BDF70Q39483891-51C3FEB1-8036-48D9-A57B-D0063A7185D3Q39974049-EF4156FD-ABF7-4D4D-AFE1-4956E117F4C7Q40057653-3AC2DD45-6E59-44D7-B98D-F3C8921F84F9Q40087031-94FFED45-1FCC-4792-BC3A-81F9522BB0F1Q40157600-96AEB6BE-7274-4195-A5B4-71BF4D63FE12Q41807753-5F5D2C88-5CFE-458C-B6C2-97BF180B886FQ52661702-C0C095A0-9470-4971-B50E-20627AFCEE18
P2860
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
High-density lipoproteins redu ...... bodies by promoting HCV entry.
@en
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus
@nl
type
label
High-density lipoproteins redu ...... bodies by promoting HCV entry.
@en
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus
@nl
prefLabel
High-density lipoproteins redu ...... bodies by promoting HCV entry.
@en
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus
@nl
P2093
P50
P921
P356
P1476
High-density lipoproteins redu ...... ibodies by promoting HCV entry
@en
P2093
Anne Op de Beeck
Cécile Voisset
Gilles Duverlie
Ngoc Vu-Dac
Pauline Horellou
P304
P356
10.1099/VIR.0.81932-0
P407
P577
2006-09-01T00:00:00Z